Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project

Blood

Volumn 117, Issue 12, 2011, Pages 3402-3408

  Weisenburger, Dennis D ^a   Savage, Kerry J ^b   Harris, Nancy Lee ^c   Gascoyne, Randy D ^b   Jaffe, Elaine S ^d   MacLennan, Kenneth A ^e   Rüdiger, Thomas ^f   Pileri, Stefano ^g   Nakamura, Shigeo ^h   Nathwani, Bharat ⁱ   Campo, Elias ^j   Berger, Francoise ^k   Coiffier, Bertrand ^k   Kim, Won Seog ^l   Holte, Harald ^m   Federico, Massimo ⁿ   Au, Wing Y ^o   Tobinai, Kensei ^p   Armitage, James O ^a   Vose, Julie M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h NAGOYA UNIVERSITY HOSPITAL   (Japan)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j HOSPITAL CLÍNIC   (Spain)

^k CENTRE HOSPITALIER LYON SUD   (France)

^l Sungkyunkwan University   (South Korea)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ Modena Hospital   (Italy)

^o QUEEN MARY HOSPITAL   (Hong Kong)

^p NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 79953124083     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-310342     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9(7):717-720. (Pubitemid 28394156)
3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
4. Abouyabis AN, Shenoy PJ, Lechowicz NJ, Flowers CR. Incidence and outcomes of peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49(11):2099-2107.
5. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9(8):849-855. (Pubitemid 28440443)
6. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13(1):140-149. (Pubitemid 34436738)
7. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15(10):1467-1475. (Pubitemid 39409735)
8. Kojima H, Hasegawa Y, Suzukawa K, et al. Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res. 2004;28(12):1287-1292.
9. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-2479. (Pubitemid 38392996)
10. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472-2479. (Pubitemid 46630624)
11. Prochazka V, Trneny M, Pytlik R, et al. Peripheral T-cell lymphoma, unspecified: the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1): 103-107.
12. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol. 2008; 26(3):152-158.
13. Lee Y, Uhm JE, Lee HY, et al. Clinical features and prognostic factors of patients with "peripheral T-cell lymphoma, unspecified." Ann Hematol. 2009;88(2):111-119.
14. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34(2):187-220.
17. Vose J, Armitage J, Weisenburger D. International Peripheral T-cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
18. Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-3918.
19. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas: Clinico-pathologic study of 168 cases according to the REAL classification. Ann Oncol. 1997;8(6):583-592.
20. Pellatt J, Sweetenham J, Pickering RM, Brown L, Wilkins B. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol. 2002;81(5):267-272. (Pubitemid 36067618)
21. Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American Lymphoma (REAL) classification. Eur J Cancer. 2002;38(1):75-81. (Pubitemid 34031829)
22. Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the Revised European-American Lymphoma classification. Leuk Lymphoma. 2003;44(2):241-249.
23. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16(2):206-214.
24. de Laval L, Bisig B, Thielen C, Boniver J, Gaulard P. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol. 2009;72(2):125-143.
25. Costello R, Sanchez C, Le Treut T, Rihet P, Imbert J, Sebahoun G. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol. 2010; 150(1):21-27.
26. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010; 115(5):1026-1036.
27. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28(9):1583-1590.
28. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005; 129(3):366-372. (Pubitemid 40646895)
29. Rodriguez J, Gutierrez A, Martinez-Delgado B, Perez-Manga G. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol. 2009;71(3):181-198.
30. Zain JM, O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol. 2010;92(1):33-44.
31. Foss FM. Enhancing existing approaches to peripheral T-cell lymphoma. Semin Hematol. 2010; 47(suppl 1):S8-S10.
32. Zinzani PL. High-dose therapy and stem cell transplantation. Semin Hematol. 2010;47(suppl 1):S15-S17.
33. Persky DO, Miller TP. Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol. 2009;21(5):401-406.
34. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010; 28(27):4170-4176.
35. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Group d'Etude des Lymphomes de l'Adulte (GELA) study. Blood. 2006;108(13):4163-4169. (Pubitemid 44913288)
36. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005; 29(10):1284-1293. (Pubitemid 41368762)
37. Geissinger E, Odenwald T, Lee SS, et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8+ cytotoxic T cells. Virchows Arch. 2004;445(4):334-343. (Pubitemid 39517757)
38. Patsouris E, Engelhard M, Zwingers T, Lennert K. Lymphoepithelioid cell lymphoma (Lennert's lymphoma): clinical features derived from analysis of 108 cases. Br J Haematol. 1993;84(2):346-348. (Pubitemid 23201711)
39. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92(1): 76-82. (Pubitemid 28303178)